March 1 (Bloomberg) -- Bristol-Myers Squibb Co., the maker of the Plavix blood-thinner, expanded its board by adding Chief Medical Officer Elliott Sigal as a director.
Sigal, 59, takes the position effective today and will become a member of the board’s science and technology committee, New York-based Bristol-Myers said. The addition brings the number of board members to 12, the average of Bristol-Myers’s U.S. pharmaceutical company peers, according to data compiled by Bloomberg.
Since Sigal became medical chief in 2004, Bristol-Myers has brought eight new drugs to market, with as many as five more approvals expected by 2012, according to the company. As medical chief, Sigal reports to Lamberto Andreotti, who replaced James Cornelius as chief executive officer a year ago. Cornelius remains as Bristol-Myers’s chairman.
“We are very excited to have Elliott join our board,” Cornelius said in a statement. “Under his leadership, our R&D organization has become one of the most-productive in the industry.”
To contact the reporter on this story: Tom Randall in New York at firstname.lastname@example.org.
To contact the editor responsible for this story: Reg Gale at email@example.com.